NCT03672604View on ClinicalTrials.gov

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 19, 2018

Primary Completion Date

July 30, 2019

Study Completion Date

July 30, 2019

Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
DRUG

NLY01

NLY01, a PEGylated form of the anti-diabetic peptide exenatide

Trial Locations (1)

78209

ICON Early Phase Services/CRU, San Antonio

Sponsors

Lead Sponsor

Neuraly, Inc.
All Listed Sponsors
lead

Neuraly, Inc.

INDUSTRY

NCT03672604 - A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects | Biotech Hunter | Biotech Hunter